EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent

Shigeru Saito, Johan Bennett, Holger M Nef, Mark Webster, Atsuo Namiki, Akihiko Takahashi, Tsunekazu Kakuta, Seiji Yamazaki, Yoshisato Shibata, Douglas Scott, Mathias Vrolix, Madhav Menon und 8 weitere

JACC: Cardiovascular Interventions · 2025-04 · 18 (8) · 988-997

DOI: 10.1016/j.jcin.2025.01.426 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-04. Verfasst von Shigeru Saito und 19 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center, Iryohojin Tokushukai Shonan Kamakura General Hospital, Kamakura City, Japan. Electronic address: transradial@kamakuraheart.org. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Percutaneous Coronary Intervention, Coronary Artery Disease, Sirolimus. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The sirolimus-eluting bioadaptor is a novel coronary implant that unlocks, separates, and maintains dynamic support of the vessel at the lesion site 6 months after percutaneous coronary intervention when the polymer coating covering the helical strands resorbs. This enables the bioadaptor to maintain the established flow lumen and to restore hemodynamic modulation of the artery, including cyclic pulsatility, vasomotion, and adaptive remodeling. OBJECTIVES: The purpose of this study was to report the first randomized clinical evidence of the DynamX bioadaptor implant through 2 years compared with the Resolute Onyx contemporary drug-eluting stent. METHODS: This multicenter, single-blind, 1:1 randomized clinical trial was conducted at 34 hospitals in Japan, Europe, and New Zealand. The eligibility criterion was de novo coronary lesions in up to 2 vessels. The sample size was based on the primary endpoint, noninferiority of 12-month target lesion failure (TLF). The authors herein report 2-year outcomes. RESULTS: In total, 445 patients were enrolled; 3 patients treated for in-stent restenosis and 2 who did not receive the assigned study device because of randomization error were excluded from the analysis. In the per-protocol population of patients with de novo native coronary lesions treated with the assigned device (n = 440), 2-year Kaplan-Meier estimates of TLF and target vessel failure rates in the bioadaptor group were lower (1.8% [4 of 219] vs 5.5% [12 of 221], risk difference -3.6% [95% CI: -7.8% to -0.0%; P = 0.044], and 1.8% [4 of 219] vs 5.9% (13 of 221), risk difference -4.1% [95% CI: -7.2% to -1.0%; P = 0.027], respectively). One clinically driven target lesion revascularization occurred between 6 months and 2 years in the bioadaptor group, whereas 2 cardiovascular deaths and 4 clinically driven target lesion revascularizations occurred in the drug-eluting stent group. The 2-year rate of definite or probable device thrombosis was 0.0% vs 0.5% (n = 1) (P = 0.32), respectively. CONCLUSIONS: This is the first report of 2-year outcomes comparing the bioadaptor implant with a contemporary drug-eluting stent. At 2-year follow-up, fewer TLF events were observed in patients treated with the bioadaptor. (The Elixir Bioadaptor vs. the Onyx Stent in De Novo Native Coronary Arteries [BIOADAPTOR RCT]; NCT04192747).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsPercutaneous Coronary InterventionCoronary Artery DiseaseSirolimusCardiovascular AgentsHumansMaleFemaleTreatment OutcomeProsthesis DesignTime FactorsAgedMiddle AgedSingle-Blind MethodEuropeNew ZealandJapanRisk FactorsCoronary Restenosis

Stichwörter der Autor:innen

bioadaptorcoronary artery diseasedrug-eluting stent(s)hemodynamic modulationpercutaneous coronary intervention

Substanzen

SirolimusCardiovascular Agents

Autor:innen und Institutionen

  • Heart Center, Iryohojin Tokushukai Shonan Kamakura General Hospital, Kamakura City, Japan. Electronic address: transradial@kamakuraheart.org.
  • Department of Cardiovascular Medicine, UZ Leuven, Leuven, Belgium.
  • Department of Cardiology and Angiology, University of Giessen, Giessen, Germany.
  • Cardiac Investigation Unit, Auckland City Hospital, Auckland, New Zealand.
  • Department of Cardiology, Kanto Rosai Hospital, Nakahara-ku, Kawasaki-shi, Japan.
  • Department of Cardiology, Takahashi Hospital, Kobe City, Japan.

Zitieren

APA

Saito, S., Bennett, J., Nef, H. M., Webster, M., Namiki, A., Takahashi, A., Kakuta, T., Yamazaki, S., Shibata, Y., Scott, D., Vrolix, M., Menon, M., Möllmann, H., Werner, N., Neylon, A., Mehmedbegovic, Z., Smits, P. C., Morice, M. C., Verheye, S., & BIOADAPTOR-RCT Collaborators (2025). Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent. JACC: Cardiovascular Interventions, 18(8), 988-997. https://doi.org/10.1016/j.jcin.2025.01.426

Vancouver

Saito S, Bennett J, Nef HM, Webster M, Namiki A, Takahashi A, et al. Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent. JACC: Cardiovascular Interventions. 2025;18(8):988-997. doi:10.1016/j.jcin.2025.01.426

BibTeX
@article{Saito2025,
  author = {Saito, Shigeru and Bennett, Johan and Nef, Holger M and Webster, Mark and Namiki, Atsuo and Takahashi, Akihiko and Kakuta, Tsunekazu and Yamazaki, Seiji and Shibata, Yoshisato and Scott, Douglas and Vrolix, Mathias and Menon, Madhav and Möllmann, Helge and Werner, Nikos and Neylon, Antoinette and Mehmedbegovic, Zlatko and Smits, Pieter C and Morice, Marie-Claude and Verheye, Stefan and BIOADAPTOR-RCT Collaborators, BIOADAPTOR-RCT Collaborators},
  title = {Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {988--997},
  doi = {10.1016/j.jcin.2025.01.426}
}
Kostenlos starten →